All Blogs
May 31, 2023
ATS 2023 Updates: Dupixent – A Ray of Hope For Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD)
DUPIXENT has shown positive pivotal results for COPD, confirming the key role of IL-4 and IL-13 in type 2 inflammatory diseases. DUPIXENT has the potential to be the first biologic with unprecedented and paradigm-shifting clinical results to treat COPD, having demonstrated a statistically significant reduc...
Read More...
May 31, 2023
Evaluating the Rising Demand & the Market Potential of the Omega-3 Products
In recent years, the demand for Omega-3 Products has risen exponentially. Omega-3 fatty acids are also referred to as Polyunsaturated fatty acids and work in the body to lower triglycerides, reduce inflammation, and improve heart health, among several other functions. As per DelveInsight’s latest assessment, the gl...
Read More...
May 30, 2023
FDA Approves Lexicon’s INPEFA (Sotagliflozin); PTC Therapeutics’s Vatiquinone MOVE-FA Registration-Directed Trial; EU Approval to Novartis’s Sickle Cell Disease Drug; EMA Approves Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLC; FDA Grants Priority Review to Fruquintinib for mCRC; FDA Orphan Drug Designation to Vega Therapeutics’s VGA039
Lexicon Announces FDA Approval of INPEFA (Sotagliflozin) For Treatment of Heart Failure Lexicon Pharmaceuticals, Inc. announced that the FDA has approved INPEFATM (sotagliflozin), a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure vis...
Read More...
May 30, 2023
ATS 2023 Updates: AD109’s Potential as the First Oral Medication for Obstructive Sleep Apnea (OSA)
Apnimed’s AD109 has the potential to be the first oral pharmaceutical drug that remedies both, the primary cause of OSA, nocturnal airway obstruction, and the daytime symptoms of OSA, such as fatigue. The dual mode of action of AD109 leads to upper airway dilatation as well as enhanced breathing and oxygen...
Read More...
May 29, 2023
ANCA-associated Vasculitis Treatment Market: Unraveling the Complexities
ANCA-associated vasculitis is a rare, life-threatening autoimmune disease with a relapsing nature. ANCA-Associated vasculitis comprises three autoimmune disorders, i.e. Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). The global yearly...
Read More...
May 26, 2023
What Lies Ahead For Parkinson’s Disease Psychosis Treatment Market?
The term “psychosis” defines a group of mental symptoms that occur when there has been a partial loss of contact with reality. A person’s thoughts and perceptions are distorted during a psychotic episode, and they could find it difficult to distinguish between tangible and intangible. Other signs include nonsensica...
Read More...
May 25, 2023
Eosolutions Corp’s Dr. Banner Balloon Guide Catheter; US FDA Approves the Cyltezo® Pen; Orlucent’s Handheld Mole Imaging System; Grünenthal’s Resiniferatoxin for Pain Associated with Knee Osteoarthritis; Element Science’s Jewel Patch Wearable Cardioverter Defibrillator; A.Menarini Diagnostics’s PRIME MDx Platform
Eosolutions Announces The Full Commercial Launch of The Dr. Banner Balloon Guide Catheter EOSolutions Corp., a forerunner in medical technology focused on offering high-quality catheter solutions, is pleased to introduce the Dr. Banner, Balloon Guide Catheter (BGC). Dr. Banner, developed in collaboration with In...
Read More...
May 24, 2023
From Paper to Pixels: The Advantages and Challenges of Electronic Health Record
In recent years, technological innovation has led to significant improvements in the healthcare delivery system. It has strengthened the efficiency of the organization and hospital and has enhanced the health outcome as well. Among various emerging technologies, Electronic Health Records (EHRs) is one of the much-a...
Read More...
Jun 10, 2025
Abbvie-Genmab’s EPKINLY/TEPKINLY Performance in DLBCL Treatment: The First CD20XCD3 Bispecific Antibody
A new era in lymphoma therapy began in 2023 when AbbVie and Genmab’s EPKINLY/TEPKINLY became the first CD20xCD3 bispecific antibody approved in the US for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). This groundbreaking approval marked a major milestone in immunother...
Read More...
May 23, 2023
FDA Approves RINVOQ for Crohn’s Disease; FDA Approves Krystal Biotech’s Gene Therapy Vyjuvek; FDA Approves EPKINLY to Treat R/R DLBCL; FDA Orphan Drug Designation to Mitazalimab; Phase 3 Trial Result of OCS-01 Eye Drops; TAGRISSO® + Chemotherapy for the EGFR-mutated Advanced Lung Cancer
FDA Approves RINVOQ as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease AbbVie announced that the FDA had approved RINVOQ® (upadacitinib) for treating people with moderately to highly active Crohn's disease who have had an unsatisfactory response or intolerance to one or more TNF blockers. Thi...
Read More...